Assenagon Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$533K Sell
21,052
-57,075
-73% -$1.26M ﹤0.01% 1064
2026
Q1
$1.74M Buy
78,127
+69,411
+796% +$1.66M ﹤0.01% 796
2025
Q4
$233K Sell
8,716
-18,900
-68% -$452K ﹤0.01% 1110
2025
Q3
$589K Sell
27,616
-1,683,979
-98% -$39.8M ﹤0.01% 1027
2025
Q2
$36.9M Sell
1,711,595
-1,951,550
-53% -$36.3M 0.05% 263
2025
Q1
$60.8M Buy
+3,663,145
New +$66.5M 0.1% 179
2022
Q3
Sell
-119,648
Closed -$1.69M 1323
2022
Q2
$1.69M Sell
119,648
-28,965
-19% -$541K 0.01% 895
2022
Q1
$3.6M Buy
148,613
+47,464
+47% +$1.15M 0.01% 624
2021
Q4
$2.36M Buy
101,149
+86,934
+612% +$1.75M 0.01% 761
2021
Q3
$236K Buy
+14,215
New +$274K ﹤0.01% 1208
2019
Q4
Sell
-19,822
Closed -$713K 744
2019
Q3
$713K Buy
+19,822
New +$601K ﹤0.01% 628

Other funds holding ACAD

Assenagon Asset Management's ACAD Position: Q2 2026 in Review

Assenagon Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 73% in Q2 2026, selling an estimated $1.26M and leaving 21,052 shares worth $533K. The position accounts for ﹤0.01% of the portfolio, ranked #1064.

Assenagon Asset Management first reported a position in ACAD in Q3 2019 and has held it in 11 quarters since. The position peaked at $60.8M in Q1 2025. 36 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Assenagon Asset Management held 21,052 shares of Acadia Pharmaceuticals worth $533K as of Q2 2026.
  • Assenagon Asset Management sold 57,075 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.26M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1064 holding.
  • Assenagon Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2019 and has held it in 11 quarters since.
  • Assenagon Asset Management's Acadia Pharmaceuticals position peaked at $60.8M in Q1 2025.
  • 36 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.